Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Chengdu Anticancer Bioscience Ltd. currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are spread across 2 distinct art units for the company patent portfolio. The prosecution involves 3 distinct examiners, matching the number of 3 pending office actions. This distribution of examiners and pending actions ensures that each application is receiving an independent review from a different official.
NESTOR, DONNA MICHELLE is the busiest examiner for the company, currently overseeing 1 pending office action. With the 3 distinct examiners assigned to the 3 pending office actions, each official is responsible for a pending matter. This distribution across 2 distinct art units shows that the pending office actions are being handled by different examiners. For the practitioner, this requires managing separate examiner relationships within the Biotechnology & Pharmaceuticals technology area, even though the work is situated in the 2 distinct art units. The 3 pending office actions are the only active matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NESTOR, DONNA MICHELLE | 1 | 56.6% | +44.2% |
| HILL, GRACELYN MARKHAM | 1 | 100.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17954969 | GRAPH BASED MACHINE LEARNING FOR GENERATING VALID SMALL MOLECULE COMPOUNDS | HILL, GRACELYN MARKHAM | 35d |
| 18667441 | 1H-BENZO[B]AZEPIN-2(3H)-ONE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | NESTOR, DONNA MICHELLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18667441 | 1H-BENZO[B]AZEPIN-2(3H)-ONE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | NESTOR, DONNA MICHELLE | — |
| Art Unit | Apps |
|---|---|
| 1685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18667441 | 1H-BENZO[B]AZEPIN-2(3H)-ONE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | NESTOR, DONNA MICHELLE | — | §103§112 | Non-Final OA | — | Pending | May 17, 2024 |
| 17954969 | GRAPH BASED MACHINE LEARNING FOR GENERATING VALID SMALL MOLECULE COMPOUNDS | HILL, GRACELYN MARKHAM | 1685 | §101§103§112 | Non-Final OA | 35d | Pending | Sep 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial